Cooperative Agreement 2507167
Award Date
6/15/25
Completion Date
5/31/27
Dollars Obligated
$1.3M
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Cooperative Agreement
Place of Performance
St Paul, MN 55113, USA
Similar Awards
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Cerflux Inc. aims to develop a personalized cancer treatment screening platform. The project will establish guidelines for handling solid tumor biopsy samples, generate 3D bioprinted tumor models for validation, and demonstrate the platform's ability to match patients with the most effective cancer treatments before treatment begins. This innovative approach has the...
This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...
This $274,594 Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports research and development of an innovative technology for cancer diagnosis and treatment. The project aims to improve molecular profiling and clinical laboratory testing of cancer samples by optimizing microdissection techniques. The research will focus on modeling and optimizing the opto-thermal-mechanical interactions involved in microdissection to...
The National Science Foundation (NSF) awarded a $1,250,000 Cooperative Agreement under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) to Micropure Genomics Inc., a minority-owned small business based in Middletown, DE. The project aims to develop an innovative platform for preparing high-quality DNA samples to support long-read sequencing technologies. The platform will automate the sample preparation process, reducing time, cost, and complexity while enhancing...
This Cooperative Agreement award, issued by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, provides $1,213,619 to Encapsulate Inc. to develop a precision oncology platform that integrates microfluidics, biochips, bioreactors, and 3D tumor models to predict patient-specific cancer drug responses. The project aims to create tumor models from patient-derived biopsy specimens, allowing oncologists to test multiple treatment options...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $305,000 to Cicadea Biotech LLC aims to develop a novel, non-invasive urine test for early detection of kidney cancer. The project objectives are to: 1) demonstrate the accuracy and specificity of the biomarker for detecting early-stage kidney cancer without symptoms, and 2) demonstrate the effectiveness of the test for detecting residual disease in post-nephrectomy kidney...
The National Cancer Institute (NCI) awarded a $400,000 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The goal of this 1-year project is to develop a novel nanopore-based sequencing approach that can accurately characterize repetitive DNA sequences, which are critical for understanding cancer progression but challenging to analyze using current sequencing...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Beken Bio, Inc. aims to develop a highly sensitive, minimally invasive laboratory test to detect early-stage ovarian cancer by assaying relevant biomarkers on circulating extracellular vesicles in patient plasma. The project will utilize a novel technology to identify key proteins in extracellular vesicles from various ovarian cancer subtypes and employ a machine...
The National Cancer Institute (NCI) awarded a $1,280,908 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Exai Bio Inc., a small disadvantaged business located in Palo Alto, California. The award period runs from September 12, 2024 to August 31, 2026. The purpose of this Project Grant is to develop a novel assay and artificial intelligence (AI) model for the early detection of non-small cell lung cancer (NSCLC) and predicting its subtypes using a novel...
The National Science Foundation awarded a $275,000 Project Grant to Oraliva, Inc. under the Technology, Innovation, and Partnerships program to develop a portable, programmable single cell cytology platform for the early detection of epithelial cancers. The platform will combine microfluidics and artificial intelligence to classify potentially cancerous tissue in near real-time through multiparameter single-cell analysis and automated evaluation. The objectives are to link different clinical...